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OBJECTIVES: Consumption of toxic species of mushrooms may have detrimental effects and increase oxidative
stress. Paraoxonase, arylesterase and glutathione-S-transferase are antioxidants that resist oxidative stress.
In this study, we analyzed the changes in these enzymes during intoxication due to mushrooms.
METHODS: The study enrolled 49 adult patients with a diagnosis of mushroom poisoning according to
clinical findings and 49 healthy volunteers as the control group. The patients with mild clinical findings were
hospitalized due to the possibility that the patient had also eaten the mushrooms and due to clinical findings in
the late period, which could be fatal. Paraoxonase, arylesterase, and glutathione-S-transferase concentrations,
as well as total antioxidant and oxidant status, were determined in the 49 patients and 49 healthy volunteers by
taking blood samples in the emergency department.
RESULTS: While paraoxonase, arylesterase, and total antioxidant status were significantly decreased in the
patient group (po0.05), glutathione-S-transferase, total oxidant status and the oxidative stress index were
significantly higher (po0.05). There was a positive correlation between the hospitalization time and the oxida-
tive stress index (r=0.752, po0.001), whereas a negative correlation was found with glutathione-S-transferase
(r=-0.420, p=0.003).
CONCLUSION: We observed a significant decrease in paraoxonase and arylesterase and an increase in
glutathione-S-transferase and oxidative stress indexes in patients with mushroom poisoning, indicating that these
patients had an oxidative status. In particular, a low total antioxidant status and high oxidative stress index may gain
importance in terms of the assessment of hospitalization duration.
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’ INTRODUCTION
Because they contain nutrients and can easily be obtained
from nature, natural mushrooms are commonly consumed
all over the world. However, the consumption of some toxic
species of mushrooms may cause serious poisoning. Clini-
cally, mushrooms mostly result in gastrointestinal findings
and are associated with a good prognosis. Depending on
the type of mushroom, different clinical situations involving
high mortality rates may occur (1,2).
Paraoxonase (PON) 1 and arylesterase (ARES) are
enzymes encoded by the same gene and have similar active
centers. PON1, also known as aromatic esterase 1 or serum
aryldialkylphosphatase 1, is a hydrolase that can hydrolyze
paraoxon, a strong inhibitor of cholinesterases, and detoxify
other types of organophosphates. The arylesterase enzyme
can detoxify organophosphates such as PON1, but it does
not exhibit a similar genetic polymorphism. Although the
natural substrates of both enzymes are different, the PON1
enzyme can hydrolyze phenyl acetate, a substrate of ARES;
therefore, it exhibits the activities of both ARES and PON (3-6).
The most prominent feature of ARES enzymes is that they
are antioxidants. The serum PON1 enzyme is responsible for
a portion of ARES (7,8).
The paraoxonase enzyme system consists of three different
groups, namely, PON1, PON2 and PON3. Substrate specifi-
cities of enzymes have lactonase activity and vary widely.
With lactonase activity, PONs become involved in the meta-
bolism of many drugs and drug precursors. They can also
recognize arachidonic acid metabolites as substrates. Addi-
tionally, phospholipase A2-like acyl-ARES activities of PON1
have been identified. However, PON2 and PON3 do not
have PON activity. PON 3 is reported to have low ARES
activity (9-11). The liver has the highest levels of PON
expression and activity. The basic synthesis of PON1 and
PON3 occurs in the liver. After synthesis, some of the enzymesDOI: 10.6061/clinics/2018/e16-550
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are transferred from the liver to the plasma through a specific
transport system (12-14).
Glutathione-S-transferase (GST) is a multi-functional enzyme
in humans that is found in many tissues and has a broad
activity and specific substrate (15-17).
With this feature, GST performs the task of defense in
living organisms exposed to potentially toxic chemicals.
GST performs detoxification by neutralizing the electrophilic
areas of reduced glutathione, which are related to the sulf-
hydryl group. The resultant product is a water-soluble mer-
capturic acid that is removed from the body by urinary
excretion (18-21). The GST enzyme system performs the
detoxification of not only drugs and chemical agents but also
some harmful molecules that occur in lipids and DNA, final
products of DNA hydroxy peroxides, and alkenol and endo-
genous electrophilic components (22).
Antioxidants that aim to prevent the damage caused by
free radicals consist of enzymes and non-enzyme molecules.
The antioxidant/oxidant status of the body can be evaluated
by separately measuring the activity of antioxidant enzymes
and the concentration of antioxidant/oxidant molecules; how-
ever, the general antioxidant/oxidant status can be evaluated
more easily by measuring the overall total antioxidant status
(TAS) (23) and overall total oxidant status (TOS) (24). Oxida-
tive stress occurs as a result of excessive oxidant formation
in the body, a decrease in the amount of antioxidants or
a combination of these situations (4). Factors that increase
oxidative stress reduce the activity of some antioxidant
enzymes, such as PON1 (25). In this study, we analyzed the
level of antioxidant enzymes (PON, ARES, and GST) as well
as the TAS, TOS, and oxidative stress index (OSI) in patients
with mushroom poisoning who were admitted to our clinic.
We also investigated the correlation of these enzymes (PON,
ARES, and GST) with TAS and TOS levels during the hospi-
talization period.
’ MATERIALS AND METHODS
This study was conducted between January 2013 and
January 2014 in 49 patients admitted to our university hospital
emergency department with mushroom poisoning and
49 healthy volunteers (total of 98 individuals).
Mushroom poisoning diagnosis was made according to
the clinical findings in the patients whose symptoms arose
within 0-24 hours after ingestion of wild mushrooms while a
mycologist was not available to analyze the gastric contents
or the mushroom toxins,. Clinical signs were cholinergic toxi-
dromes, anticholinergic syndrome, central nervous system
signs, early onset of gastrointestinal (GI) symptoms (e.g.,
cramps, vomiting, and increased bowel activity) and delayed
GI symptoms such as hepato-renal toxicity. We also excluded
diseases associated with the differential diagnosis (acute
kidney injury, acute liver failure, adrenal crisis, bacterial
gastroenteritis, food allergies, food poisoning, hallucinogen
use, hemorrhagic shock, hepatic encephalopathy, hepator-
enal syndrome, isoniazid toxicity, pediatric asthma, septic
shock, and viral gastroenteritis) based on the patient history
and laboratory results.
A 5-ml sample of blood was obtained from the brachial
vein within the first hour following admission for measure-
ment of GST, ARES and PON1, placed in a sterile vacuum
tube, and sent to the biochemistry laboratory. After the blood
was centrifuged, the sample was stored in a refrigerator at
-80oC. Measurement of serum paraoxonase and ARES activities.
PON1 enzyme activity was performed with a spectro-
photometer by measuring the p-nitrophenol absorbance
increase within one minute at an ambient temperature of
25oC and wavelength of 412 nm. P-nitrophenol was obtained
by paraoxan hydrolysis. The serum PON1 activity determi-
nation was performed by modification of the Eckerson,
Furlang, Juretic, and Mackness methods (26). Phenyl-acetate
was used as a substrate to measure ARES activity. One unit
of ARES activity was determined as the mmol phenol that
developed within one minute, and the results were expressed
as kU/L (27).
Measurement of serum total antioxidant status
Serum total antioxidants were measured by the auto-
matic measurement method based on the procedure in which
the characteristic color formed by the TAS 2,2’-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid) radical was lightened
with the antioxidants in the sample (23). The results are
expressed as mmol Trolox equivalents/L.
Measurement of serum total oxidant status
We determined TOS by the automatic measurement
method (24). The method involves the conversion of the ferrous
ion-o-dianisidine complex in the sample to a ferric ion. The
ferric ion forms a colored complex with xylenol orange in
an acidic medium. The intensity of color measured by the
spectrophotometer is associated with the total quantity of
oxidant molecules in the sample. The measurement was
calibrated with hydrogen peroxide (H2O2), and the results
are expressed as micro-molar H2O2 equivalents per liter
(mmol H2O2 equiv./L).
Determination of GST activity
The volume was increased to 1000 ml by adding 50 ml of
20 mM GSH to 50 ml of 0.2 M sodium phosphate buffer
(pH=6.5) and by adding distilled water to 50 ml of 20 mM
CDNB and 50 ml of enzyme extract. One unit of enzyme
activity is the amount of enzyme that catalyzes 1 mmol product
in 1 minute at 30oC, and the activities were calculated based on
the increase in the absorbency against the blank at 340 nm and
30oC (28).
OSI was calculated according to the following formula:
OSI: TOS/TASx100.
Statistical analysis
Continuous variables are expressed as the mean±SD
or medians (min-max) in the presence of abnormal distribu-
tions, and categorical variables are expressed as percentages.
Comparisons between groups of patients were performed
using the w2 test for categorical variables, independent samples
t test for normally distributed continuous variables, and Mann-
Whitney U test when the distribution was skewed. Correla-
tions were evaluated using the Spearman correlation test.
The Kruskal-Wallis test was used for comparison of enzyme
levels according to the length of hospital stay. All statistical
procedures were performed using SPSS software version 14.0
(SPSS Inc., Chicago, IL, USA). A p-value of 0.05 was considered
significant.
Ethics
The study was approved by the Cumhuriyet University
Ethics Committee in Sivas, Türkiye (2009-09/85). The study
adhered to the tenets of the Declaration of Helsinki.
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’ RESULTS
The difference between the age groups and genders of the
patients enrolled in the study was insignificant (p40.05).
ARES and PON levels were significantly decreased due to
the increased oxidative stress, whereas TOS and GST levels
in the patient group increased. When the groups were com-
pared in terms of OSI, the difference between the groups was
significant (Table 1).
When the correlation analysis of TAS, TOS, OSI, GST,
ARES and PON levels in the patient group was made based
on the length of stay, the differences in the TAS, TOS, OSI,
and GST levels were significant, while those in the ARES and
PON levels were insignificant (Table 2, Figures 1 and 2).
Length of stay was moderately negatively correlated with
GST (r=-0.420, p=0.003; Figure 1), TAS (r=-0.548, po0.001),
and TOS levels (r=0.435, p=0.002) and strongly positively
correlated with OSI (r=0.752, po0.001; Figure 2). There was
no significant correlation between the length of stay and the
other laboratory findings (p40.05).
Enzyme levels according to the length of stay are provided
in Table 3.
The duration of hospitalization in patients with lower
levels of GST was found to be longer.
’ DISCUSSION
PONs are enzymes with antioxidant effects. PON1 shows
a protective effect through the detoxification of neurotoxic
agents, such as acute organophosphate insecticides and soman-
sarine, and especially against lipid peroxidation, which is
very important in atherosclerosis and diabetes pathogenesis.
Therefore, it is suggested that increasing the activity and/or
concentration of serum PON1 would be useful for the treat-
ment of the disease which increase the oxidative status (29-31).
Although the main substrate of PON1 in the human body is
unknown, its direct or indirect antioxidant effect seems to be
its main effect. PON1 decreases during many infections and
inflammation, due to the consumption. Similarly, a reduced
PON was observed in relation to the endothelial damage in
the eyes of patients with acute silk road disease (32,33). In
our study, compared with healthy individuals, we found that
PON activity was significantly low in the patients.
The most prominent features of ARES and PON1 are their
antioxidant effects. In a study where PON1 and ARES activi-
ties in patients with pulmonary hypertension were exam-
ined, both enzymes were reduced depending on oxidative
stress, and the results are consistent with those of the present
study (7).
In another study, compared with the PON and ARES acti-
vities in the patients in the control group, those in the
patients with multi-trauma were significantly lower, and
it was suggested that consideration of these enzymes in
diagnosis and treatment could be useful for assessing the
severity of the trauma and the potential effectiveness of
the treatment (34). Oxidative stress affects PON1 expression
and activity (35). Serum PON1 expression decreases with
oxidative stress (36), and PON1 even becomes inactivated
under oxidative stress (37).
Table 1 - Baseline characteristics of the study patients.
Patients (n=49) Controls (n=49) p
Mean age (years) 47±15 46±13 0.657
Male/Female 27/22 25/24 0.544
TAS 0.8±0.2 0.9±0.3 0.144
TOS 9 (4-18) 7 (3-9) o0.001
ARES 4421±1292 7162±1985 o0.001
PON 68±24 104±42 o0.001
GST 2.4 (0.6-5.4) 1.6 (2.6-5.0) 0.002
OSI 1.1 (0.4-3.18) 0.8 (0.3-2.5) o0.001
Table 2 - Spearman correlation coefficients for the length of stay.
Length of stay
r p-value
TAS -0.548 o0.001
TOS 0.435 0.002
OSI 0.752 o0.001
GST -0.420 0.003
ARES -0.139 0.339
PON 0.042 0.776
Figure 1 - Correlation between the oxidative stress index and length
of stay.
Figure 2 - Correlation between GST and length of stay.
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In the study conducted by Eren et al. (2), PON1 enzyme
levels of patients with mushroom poisoning were measured
at the time of arrival and discharge. The enzyme levels at
discharge were found to be higher. The researchers attributed
this result to the fact that the enzyme decreased during detoxi-
fication during the acute poisoning period and increased
again in the following period.
Kati et al. compared the PON, malonyldialdehyde, TAS
and ARES levels of 11 patients treated for SSRI poisoning,
and while the PON and ARES levels were significantly low,
the TAS level was significantly high (38). In our study, con-
sistent with the literature, the PON and ARES levels were
significantly lower in the patient group compared with those
in the control group. The finding that both enzymes had low
levels suggests that they may have been decreased due
to their use during the detoxification process. GSTs are an
important group of enzymes that eliminate the toxic effects
of xenobiotics and electrophilic compounds and thereby
prevent alkylation of macromolecules (DNA, RNA, proteins)
in cells (39).
GSTs perform the task of detoxification by neutralizing the
electrophilic areas of reduced glutathione, which are related
to the SH group. In the literature, we did not find any study
that investigated the relationship between GST enzymes and
intoxication. In some studies, compared with GST enzymes
in healthy controls, GST enzymes were significantly higher in
patients with complex regional pain syndrome (40). In rats
exposed to cold temperatures for a long time, GST enzymes
were significantly higher (41).
Oxidative stress is a condition that occurs in many diseases
as a result of excessive oxidant formation in the body,
a decrease in the amount of antioxidants or a combination of
these situations. Antioxidant defense mechanisms of organ-
isms, which consist of many enzymes and antioxidant com-
pounds, work to eliminate oxidants. In instances where
antioxidant mechanisms fail, oxidative stress increases and
tissue damage occurs. The intake of a high ratio of vitamins A,
E and C and antioxidants such as selenium reduces the risk of
certain diseases (42-45).
Several studies have shown that elevated OSI levels are
associated with inflammatory bowel disease, pemphigus vulgaris,
Crimean-Congo hemorrhagic fever, essential thrombocythemia,
and various clinical illnesses (46-50).
In our study, the correlation between hospitalization time
and PON, ARES, GST, OSI˙, TAS and TOS levels was investi-
gated. There was no correlation between PON and ARES
levels. A negative correlation was found between TAS and
GST, whereas a positive correlation was found between TOS
and OSI. TOS and OSI levels measured at the time of the
patient’s first arrival may be a poor marker of prognosis.
Especially low TAS and high OSI levels may become impor-
tant factors for assessing hospitalization time.
In conclusion, we observed a significant decrease in
PON and ARES and an increase in OSI and GST levels in
patients with wild mushroom poisoning, indicating that
these patients had an oxidative status. However, these results
are not sufficient to explain the relationship between anti-
oxidants and mushroom poisoning. Further studies are
required to clarify the possible mechanisms underlying the
decreased and increased levels of these factors.
Limitations
Our study had several limitations. The patients admitted
to our emergency department had only mild GI symptoms
that occurred in the first 6 hours. We could not identify the
mushroom types and toxins, so we could not evaluate the
possible differences in antioxidant status with regard to
serious cases. Moreover, only PON, ARES, OSI, and GST
were examined in our study. An evaluation of more
parameters may yield better results and contribute to an
increased understanding of the pathophysiology of mush-
room poisoning.
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